TY - JOUR
T1 - ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
AU - RV306
AU - RV328 study groups
AU - Costanzo, Margaret C.
AU - Paquin-Proulx, Dominic
AU - Schuetz, Alexandra
AU - Akapirat, Siriwat
AU - Shubin, Zhanna
AU - Kim, Dohoon
AU - Wieczorek, Lindsay
AU - Polonis, Victoria R.
AU - Trinh, Hung V.
AU - Rao, Mangala
AU - Anenia, Hanna
AU - Barrera, Michael D.
AU - Boeckelman, Jacob
AU - Nails, Barbara
AU - Thapa, Pallavi
AU - Zemil, Michelle
AU - Sacdalan, Carlo
AU - Kroon, Eugene
AU - Kaewboon, Boot
AU - Tipsuk, Somporn
AU - Jongrakthaitae, Surat
AU - Gurunathan, Sanjay
AU - Sinangil, Faruk
AU - Kim, Jerome H.
AU - Robb, Merlin L.
AU - Ake, Julie A.
AU - O’Connell, Robert J.
AU - Pitisutthithum, Punnee
AU - Nitayaphan, Sorachai
AU - Chariyalertsak, Suwat
AU - Eller, Michael A.
AU - Phanuphak, Nittaya
AU - Vasan, Sandhya
N1 - Publisher Copyright:
© 2023, Costanzo et.
PY - 2023
Y1 - 2023
N2 - The RV144 phase III vaccine trial demonstrated that ALVAC-HIV and AIDSVAX B/E administration over 6 months resulted in 31% efficacy in preventing HIV acquisition, while administration of AIDSVAX B/E alone in both VAX003 and VAX004 studies failed to show efficacy. In this study, we aimed to understand the impact of ALVAC-HIV on the development of cellular, humoral, and functional immune responses compared to the administration of AIDSVAX B/E alone. ALVAC-HIV in combination with 3 doses of AIDSVAX B/E significantly increased CD4+ HIV-specific T cell responses, polyfunctionality, and proliferation compared with 3 doses of AIDSVAX B/E alone. Additionally, Env-specific plasmablasts and A244-specific memory B cells were identified with a significantly higher magnitude in the group that received ALVAC-HIV. Subsequently, data revealed increased magnitude of plasma IgG binding to and avidity for HIV Env in participants who received ALVAC-HIV compared with 3 doses of AIDSVAX B/E alone. Lastly, levels of the Fc-mediated effector functions antibody-dependent cellular cytotoxicity, NK cell activation, and trogocytosis were significantly increased in participants who received ALVAC-HIV compared with those receiving AIDSVAX B/E alone. Taken together, these results suggest that ALVAC-HIV plays an essential role in developing cellular and humoral immune responses to protein-boosted regimens relative to protein alone.
AB - The RV144 phase III vaccine trial demonstrated that ALVAC-HIV and AIDSVAX B/E administration over 6 months resulted in 31% efficacy in preventing HIV acquisition, while administration of AIDSVAX B/E alone in both VAX003 and VAX004 studies failed to show efficacy. In this study, we aimed to understand the impact of ALVAC-HIV on the development of cellular, humoral, and functional immune responses compared to the administration of AIDSVAX B/E alone. ALVAC-HIV in combination with 3 doses of AIDSVAX B/E significantly increased CD4+ HIV-specific T cell responses, polyfunctionality, and proliferation compared with 3 doses of AIDSVAX B/E alone. Additionally, Env-specific plasmablasts and A244-specific memory B cells were identified with a significantly higher magnitude in the group that received ALVAC-HIV. Subsequently, data revealed increased magnitude of plasma IgG binding to and avidity for HIV Env in participants who received ALVAC-HIV compared with 3 doses of AIDSVAX B/E alone. Lastly, levels of the Fc-mediated effector functions antibody-dependent cellular cytotoxicity, NK cell activation, and trogocytosis were significantly increased in participants who received ALVAC-HIV compared with those receiving AIDSVAX B/E alone. Taken together, these results suggest that ALVAC-HIV plays an essential role in developing cellular and humoral immune responses to protein-boosted regimens relative to protein alone.
UR - http://www.scopus.com/inward/record.url?scp=85158076140&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.167664
DO - 10.1172/jci.insight.167664
M3 - Article
C2 - 37154156
AN - SCOPUS:85158076140
SN - 2379-3708
VL - 8
JO - JCI Insight
JF - JCI Insight
IS - 9
M1 - e167664
ER -